Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral inducer of endogenous interferons that acts via the TLR7 pathway. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the potency, safety and tolerability profile of ANA598, which may not be duplicated in future cohorts at higher doses or future clinical studies of longer duration; (ii) the belief that ANA598 is a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV; (iii) the expectation that ANA598 will be active in long-term studies in combination with pegylated interferon and ribavirin and the ability to dose ANA598 for up to 48 weeks in future combination studies; (iv) the ability of Anadys to transition into Phase II studies of ANA598 during 2009; and (v) expectations regarding the evolution of the market for HCV therapies. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies (including those described in this press release) may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues, will have favorable results in future clinical trials, will maintain fast track designation or will receive regulatory approval. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015  CytomX Therapeutics, Inc., a biopharmaceutical ... today announced the filing of a registration statement on ... (SEC) relating to a proposed initial public offering of ... offered and the price range for the offering have ... common stock under the symbol "CTMX" on the NASDAQ ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Bevacizumab Market ,2010-2019" report ... the trade name of Avastin, bevacizumab injection is the ... it was approved by CFDA to treat metastatic colorectal ... all come from Roche and its subsidiary ...
(Date:8/28/2015)... 28, 2015  Today, in final recognition of the ... Health Week, 1-800 Contacts is sharing how to keep ... lens wearers who do not properly care for their ... infections. Most contact lens wearers understand ... clean lens case is sometimes overlooked.  When proper steps ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... Reportlinker.com announces that a new market ... Stakeholder Opinions: Vaccines in ... Brazil, Mexico and Argentina ... the past decade, vaccines have resurfaced as ...
... Md., Nov. 4, 2010 The U.S. Food and ... pathway to market for mammography systems that produce computerized ...   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo:   http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ... Digital Mammography Systems, are an alternative to mammography systems ...
Cached Medicine Technology:Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 2Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 3Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 4Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 5Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 6Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 7Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 8FDA Reclassifies Certain Digital Mammography Devices 2FDA Reclassifies Certain Digital Mammography Devices 3
(Date:8/30/2015)... ... August 31, 2015 , ... ... third of tax receipts, issues that are critically important to them are often ... attorneys and lobbyists monitoring proposed legislation and changing tax and regulatory policies. Smaller ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... announce that Partner Daniel M. Kotin was recently elected to membership in the ... the highest degree of peer recognition and outstanding professionalism. , ABOTA is ...
(Date:8/30/2015)... ... 2015 , ... Natural Rest contains a unique mixture of vitamins and herbs ... which help to improve mood disorders and anxiety. Like all other Creative Medical Health ... field of regenerative medicine conducted by Dr. Amit Patel of the University of Utah, ...
(Date:8/29/2015)... ... , ... Rio Salado College President Chris Bustamante announced on Aug. ... Strategic Initiatives and Information Services. O’Shea, who has served Rio Salado for the last ... impact through innovative technologies and strategies. , “I am very proud to be able ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... scrotal support and protection against dribbled urine and sweat. "In order to prevent ... N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for ...
Breaking Medicine News(10 mins):Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 2Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 3Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 4Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2
... for its high standards in nursing quality, today announced the ... excellence. The honor is determined by the American Nurses ... best in patient care. The ANCC notified Northwestern Memorial ... status sets our hospital apart and places us amongst a ...
... conducting basic research on ion channels have demonstrated a ... pain., Targeting these ion channels pharmacologically would offer effective ... painkilling drugs, according to their paper, published in a ... is the most common symptom of injuries and diseases, ...
... -- Among people with rheumatoid arthritis, 11 percent of those ... had been seeing one for quite a while. In ... other medical words related to rheumatoid arthritis, such as "osteoporosis" ... noted that previous findings have suggested that low levels of ...
... stop unwanted intruders, the skin serves as a barrier protecting ... microbes people come in contact with every day. In patients ... skin disease, the skin barrier is leaky, allowing intruders ... be sensed by the skin and subsequently wreak havoc on ...
... By Steven Reinberg HealthDay Reporter , ... percent of American adults say they had difficult childhoods ... who were absent due to separation or divorce, federal ... said that while growing up they underwent five or ...
... Social Graph app, researchers in the ADVANCE project at ... to help women scientists and engineers supercharge their careers. ... balance sheets. They,re webs of human interaction," said Nancy ... Technology and the ADVANCE project leader. "The complex structure ...
Cached Medicine News:Health News:Northwestern Memorial maintains top status in nursing hospital renewed for Nurse Magnet® 2Health News:Ion channel responsible for pain identified by UB neuroscientists 2Health News:Patient Literacy Problems Can Hinder Rheumatoid Arthritis Care 2Health News:Study reveals major shift in how eczema develops 2Health News:Study reveals major shift in how eczema develops 3Health News:Majority of U.S. Adults Had Troubled Childhoods: CDC 2Health News:Majority of U.S. Adults Had Troubled Childhoods: CDC 3Health News:Mapping faculty social networks helps female faculty move ahead at NJIT 2Health News:Mapping faculty social networks helps female faculty move ahead at NJIT 3
... this is the universal lithotripter for ... urinary and biliary treatment. The system ... with other applications including cystoscopy, ureteronoscopy, ... system comprises the height adjustable urologist' ...
... This therapeutic system ... the patient in mind. ... surgery and ongoing therapy, ... low-risk and effective therapy. ...
... Reach a new dimension! That of the ... unequalled performance and ease of use. Enjoy ... electroconductive shock wave technology coupled with the ... system. Manage the patient treatment, X-ray and ...
... The MINILITH SL1 developed by STORZ ... of extensive experience in the field of ... of the specific requirements to be met ... therapy, as has been outlined above. The ...
Medicine Products: